



200 First Street SW
Rochester, Minnesota 55905
507-284-2511

December 3, 2012

The President of the United States
The White House
Washington, DC 20500

Dear Mr. President,

I want to congratulate you on your re-election, and I applaud your efforts to reach across the aisle to bring the country together to deal with our nation's fiscal crisis.

As CEO of Mayo Clinic, I want to offer our help as you work to find solutions to our nation's financial challenges in health care. For nearly 150 years, Mayo Clinic has delivered team-based care, and patients have greatly benefitted from our "bench-to-bedside" translational approach to clinical research.

Our care of more than a million patients annually gives us a unique perspective on health care. The pending across-the-board cuts in reimbursement to physicians and hospitals will harm Medicare and have downstream negative effects on the system. Modernizing the regulatory and reimbursement framework for Medicare is essential to lowering costs and capturing the benefits of science for patients — from new clinical lab tests, which are essential to delivering personalized, cost-effective treatments, to the miracle of regenerative medicine.

Mayo Clinic's work in applying the discipline and rigor of science and engineering to health care delivery would be particularly valuable as you seek to transition Medicare from a volume-based system to one that truly rewards high value, patient-centered care. This emerging science of health care delivery is a key translational research tool to achieve value in health care.

We have invested significantly in defining this new science. Our research already has produced sound, evidence-based clinical and managerial changes, which are driving greater efficiency, improved care for patients, and reduced costs at Mayo Clinic. For example, by following a standard protocol in our cardiovascular surgery program in a short period of time, we have reduced transfusions by 50 percent, transfusion-related complications in patients by 40 percent and costs by \$15 million.

Our research in the science of health care delivery and our work mining the combined value of clinical and cost data speaks to the perspective we can offer. We stand ready to share our expertise with you and Congress as you seek to improve the sustainability of our health care system.

Sincerely,

A handwritten signature in black ink that reads "John H. Noseworthy". The signature is fluid and cursive, with a large loop at the end of the last name.

John H. Noseworthy, MD
President and CEO
Mayo Clinic

cc: Secretary Kathleen Sebelius



200 First Street SW
Rochester, Minnesota 55905
507-284-2511

December 3, 2012

The Honorable John Boehner
Speaker of the House of Representatives
Washington, D.C. 20515

Dear Mr. Speaker,

Thank you for your service to our country and in particular, for your leadership in the United States House of Representatives.

As CEO of Mayo Clinic, I want to offer our help as you work to find solutions to our nation's financial challenges in health care. For nearly 150 years, Mayo Clinic has delivered team-based care, and patients have greatly benefitted from our “bench-to-bedside” translational approach to clinical research.

Our care of more than a million patients annually gives us a unique perspective on health care. The pending across-the-board cuts in reimbursement to physicians and hospitals will harm Medicare and have downstream negative effects on the system. Modernizing the regulatory and reimbursement framework for Medicare is essential to lowering costs and capturing the benefits of science for patients — from new clinical lab tests, which are essential to delivering personalized, cost-effective treatments, to the miracle of regenerative medicine.

Mayo Clinic’s work in applying the discipline and rigor of science and engineering to health care delivery would be particularly valuable as you seek to transition Medicare from a volume-based system to one that truly rewards high value, patient-centered care. This emerging science of health care delivery is a key translational research tool to achieve value in health care.

We have invested significantly in defining this new science. Our research already has produced sound, evidence-based clinical and managerial changes, which are driving greater efficiency, improved care for patients, and reduced costs at Mayo Clinic. For example, by following a standard protocol in our cardiovascular surgery program in a short period of time, we have reduced transfusions by 50 percent, transfusion-related complications in patients by 40 percent and costs by \$15 million.

Our research in the science of health care delivery and our work mining the combined value of clinical and cost data speaks to the perspective we can offer. We stand ready to share our expertise with you and Congress as you seek to improve the sustainability of our health care system.

Sincerely,

A handwritten signature in black ink, reading "John H. Noseworthy". The signature is fluid and cursive, with a large, prominent loop at the end of the word "Noseworthy".

John H. Noseworthy, MD
President and CEO
Mayo Clinic



200 First Street SW
Rochester, Minnesota 55905
507-284-2511

December 3, 2012

The Honorable Harry Reid
United States Senate
Washington, DC 20510

Dear Senator Reid,

Thank you for your service to our country and in particular, for your leadership in the United States Senate.

As CEO of Mayo Clinic, I want to offer our help as you work to find solutions to our nation's financial challenges in health care. For nearly 150 years, Mayo Clinic has delivered team-based care, and patients have greatly benefitted from our “bench-to-bedside” translational approach to clinical research.

Our care of more than a million patients annually gives us a unique perspective on health care. The pending across-the-board cuts in reimbursement to physicians and hospitals will harm Medicare and have downstream negative effects on the system. Modernizing the regulatory and reimbursement framework for Medicare is essential to lowering costs and capturing the benefits of science for patients — from new clinical lab tests, which are essential to delivering personalized, cost-effective treatments, to the miracle of regenerative medicine.

Mayo Clinic’s work in applying the discipline and rigor of science and engineering to health care delivery would be particularly valuable as you seek to transition Medicare from a volume-based system to one that truly rewards high value, patient-centered care. This emerging science of health care delivery is a key translational research tool to achieve value in health care.

We have invested significantly in defining this new science. Our research already has produced sound, evidence-based clinical and managerial changes, which are driving greater efficiency, improved care for patients, and reduced costs at Mayo Clinic. For example, by following a standard protocol in our cardiovascular surgery program in a short period of time, we have reduced transfusions by 50 percent, transfusion-related complications in patients by 40 percent and costs by \$15 million.

Our research in the science of health care delivery and our work mining the combined value of clinical and cost data speaks to the perspective we can offer. We stand ready to share our expertise with you and Congress as you seek to improve the sustainability of our health care system.

Sincerely,

A handwritten signature in black ink, appearing to read "John H. Noseworthy". The signature is fluid and cursive, with a large, prominent loop at the end.

John H. Noseworthy, MD
President and CEO
Mayo Clinic